A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)

Inclusion Criteria

• •Positive hepatitis B surface antigen (HBsAg) for at least 6 months prior to screening
• •Positive anti-delta for at least 3 months prior to screening
• •Positive hepatitis D virus (HDV) ribonucleic acid (RNA)
• •A liver biopsy obtained within the past 18 months for non-cirrhotic patients and 30 months for cirrhotic patients demonstrating liver disease consistent with chronic hepatitis D (CHD)
• •Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of test drug